NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group

Pharmaphorum

2 June 2021 - NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK.

The cost-effectiveness agency’s initial assessment is that Evrysdi is simply too expensive at its current price to be provided to the roughly 1,500 people with the rare genetic disorder who might be eligible to receive it.

Read Pharmaphorum article

Michael Wonder

Posted by:

Michael Wonder